Feb 7, 2025 · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria; Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies

EMBLAVEO for complicated intra-abdominal infections in adults caused by designated susceptible gram-negative microorganisms. See full Prescribing Information.

EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enter...

5 days ago · Overview: Emblaveo is an intravenous (IV) antibiotic that is used for certain infections in the abdomen or stomach area caused by bacteria. Common side effects include anemia and diarrhea.Call ...

6 days ago · EMBLAVEO is a medication that combines two components: aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor that protects aztreonam from serine β-lactamase hydrolysis and ...

Mar 22, 2024 · Emblaveo is an antibiotic used in adults to treat: Complicated (difficult to treat) intra-abdominal (belly) infections; Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay), including ventilator-associated pneumonia (pneumonia that develops in patients who use a machine called a ventilator to help them ...

Apr 22, 2024 · EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria

Aztreonam/avibactam, sold under the brand name Emblaveo, is a fixed-dose combination antibacterial medication used for the treatment of aerobic Gram-negative infections. [4] It is a combination of aztreonam, a monobactam antibacterial; and avibactam, a beta-lactamase inhibitor. [4] It was developed by AbbVie and Pfizer. [4] [5] [6]

Mar 22, 2024 · If approved, EMBLAVEO® will be indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with ...

2 days ago · Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV infusion. The ...